Dillico
Dillico is a deeptech startup (Meylan/Grenoble, France) developing an integrated, continuous and digitized manufacturing solution for mRNA drug products. The company focuses on a flow-chemistry based, all-scale approach that aims to produce formulated mRNA-LNPs from development through commercial scale using the same equipment, and to provide associated automation, analytics and process development services.
Industries
Nr. of Employees
small (1-50)
Products
Integrated continuous mRNA-LNP manufacturing platform
An integrated, compact continuous platform that combines flow-chemistry formulation, downstream unit operations and digitized control to produce formulated mRNA-LNPs across development and commercial scales.
All-ScaleFlow
A continuous and automated mRNA-LNP manufacturing system designed to produce mRNA vaccines and therapies at any scale, from discovery to commercial manufacturing, using the same piece of equipment.
Process Performance Modeling Platform
A precise process engineering and modeling platform adaptable across different RNA-based products and manufacturing requirements to optimize IVT reactions and reduce scale-up risk.
Evidence Package
An evidence package providing demonstrations with user-specified sequences and raw materials for mRNA-LNP production, delivered in about 3 months.
Integrated continuous mRNA-LNP manufacturing platform
An integrated, compact continuous platform that combines flow-chemistry formulation, downstream unit operations and digitized control to produce formulated mRNA-LNPs across development and commercial scales.
All-ScaleFlow
A continuous and automated mRNA-LNP manufacturing system designed to produce mRNA vaccines and therapies at any scale, from discovery to commercial manufacturing, using the same piece of equipment.
Process Performance Modeling Platform
A precise process engineering and modeling platform adaptable across different RNA-based products and manufacturing requirements to optimize IVT reactions and reduce scale-up risk.
Evidence Package
An evidence package providing demonstrations with user-specified sequences and raw materials for mRNA-LNP production, delivered in about 3 months.
Services
Downstream, encapsulation and formulation development, scale-down experiments, process characterization and transfer to pilot/GMP-like systems.
Automation strategy, PLC/DCS integration, FAT/SAT/IQ/OQ preparation and execution, and supplier coordination for GMP equipment.
Development of inline digital twin, dashboards, data pipelines and historian/database solutions for process monitoring and decision support.
Pilot-scale testing, proof-of-concept validation and support for early commercialization of continuous manufacturing equipment.
Downstream, encapsulation and formulation development, scale-down experiments, process characterization and transfer to pilot/GMP-like systems.
Automation strategy, PLC/DCS integration, FAT/SAT/IQ/OQ preparation and execution, and supplier coordination for GMP equipment.
Development of inline digital twin, dashboards, data pipelines and historian/database solutions for process monitoring and decision support.
Pilot-scale testing, proof-of-concept validation and support for early commercialization of continuous manufacturing equipment.
Expertise Areas
- Continuous mRNA manufacturing
- mRNA-LNP formulation and encapsulation
- Downstream process development (chromatography, TFF, sterile filtration)
- Process modeling, DoE and scale-down development
Key Technologies
- Meso-fluidic flow chemistry
- Continuous manufacturing platforms
- Lipid nanoparticle (LNP) formulation
- Chromatography for large molecules
News & Updates
Announcement of a €7.5M financing round to launch commercialization of its continuous mRNA manufacturing equipment; notes proof-of-concept validated on an industrial pilot and planned commercialization.
Presentation describing meso-fluidic continuous flow approach, real-time control and reduction of hold times for mRNA manufacturing.
Public reveal of 3D design showing high integration and ergonomics; emphasizes consolidation of multiple skids into a compact continuous system.
Completed a €7.5 million fundraising round with multiple investors to accelerate commercialization following pilot validation.
Awarded the Grand Prix i‑Lab 2023 recognizing the project as among the most promising innovation start-ups in France.
Signed a CRADA to test and adapt a continuous mRNA manufacturing solution for low- and middle-income countries.
Announcement of a €7.5M financing round to launch commercialization of its continuous mRNA manufacturing equipment; notes proof-of-concept validated on an industrial pilot and planned commercialization.
Presentation describing meso-fluidic continuous flow approach, real-time control and reduction of hold times for mRNA manufacturing.
Public reveal of 3D design showing high integration and ergonomics; emphasizes consolidation of multiple skids into a compact continuous system.
Completed a €7.5 million fundraising round with multiple investors to accelerate commercialization following pilot validation.
Awarded the Grand Prix i‑Lab 2023 recognizing the project as among the most promising innovation start-ups in France.
Signed a CRADA to test and adapt a continuous mRNA manufacturing solution for low- and middle-income countries.